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http://www.biomedcentral.com/1471-2407/12/192RESEARCH ARTICLE Open AccessMethylseleninic acid restricts tumor growth in
nude mice model of metastatic breast cancer
probably via inhibiting angiopoietin-2
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Background: Angiopoietin-2 (Ang-2) plays critical roles in vascular morphogenesis and its upregulation is
frequently associated with various tumors. Previous studies showed that certain selenium compounds possess
anti-tumor effects. However, the underlining mechanism has not been elucidated in detail. Plus, results of research
on the anti-tumor effects of selenium compounds remain controversial.
Methods: We investigated levels of Ang-2 and vascular endothelial growth factor (VEGF) on the estrogen-
independent bone metastatic mammary cancer (MDA-MB-231) cells in response to treatment by methylseleninic
acid (MSeA), and further examined the effects of MSeA oral administration on xenograft mammary tumors of
athymic nude mice by RT-PCR, Western, radioimmuno assay, and Immunohistochemistry.
Results: Treatment of MDA-MB-231 cells with MSeA caused significant reduction of Ang-2 mRNA transcripts and
secretion of Ang-2 proteins by the cells. Level of VEGF protein was accordingly decreased following the treatment.
Compared with the controls, oral administration of MSeA (3 mg/kg/day for 18 days) to the nude mice carrying
MDA-MB-231 induced tumors resulted in significant reduction in xenograft tumor volume and weights, significant
decrease in microvascular density, and promotion of vascular normalization by increasing pericytes coverage. As
expected, level of VEGF was also decreased in MSeA treated tumors.
Conclusions: Our results point out that MSeA exerts its anti-tumor effects, at least in part, by inhibiting the
Ang-2/Tie2 pathway, probably via inhibiting VEGF.
Keywords: Selenium, MSeA, Ang-2, VEGF, MDA-MB-231 cells, Xenograft tumorBackground
Selenium is an essential micronutrient element with a
number of physiological functions in human. Trace
amounts of Selenium are necessary for proper cellular
function as components of the enzymes glutathione per-
oxidase and thioredoxin reductase, which indirectly
reduce certain oxidized molecules in animals [1]. Selen-
ium is also found in three deiodinase enzymes that con-
vert one thyroid hormone to another [2]. A clear link* Correspondence: csama@sina.com; rlma@genetics.ac.cn
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reproduction in any medium, provided the orbetween selenium and thyroid function was established,
and optimal intake of selenium not only aids preserva-
tion of general health but also contributes substantially
to the prevention of thyroid disease [3]. Several studies
suggested possible links between cancer and selenium
deficiency [4-7].
Results of researches on the anti-tumor effects of sel-
enium compounds, however, remain controversial. Some
studies showed selenium induced apoptosis and cell
cycle arrest of prostate cancer cells in vitro [8-12]. Selen-
ium decreased endothelial MMP-2 and VEGF in epithe-
lial cancer cells, inhibited the mitosis and induced G1
arrest of umbilical vein endothelial [13-16]. Recent stud-
ies showed that MSeA treatment could downregulate
hypoxia-inducible factor-1α in invasive prostate cancer
[17]. At in vivo level, oral MSeA treatment of xenograft. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Figure 1 Inhibition of Ang-2 mRNA transcripts and Ang-2
protein secretion in cultured mammary cancer cells by the
MSeA treatment. MDA-MB-231 cells were treated with selected
concentrations of MSeA at the designated time intervals. Cellular
mRNA and total protein from MSeA treated cells were isolated for
subsequent quantitative analysis. A. Compared with the PBS
controls, levels of Ang-2 mRNA in MDA-MB-231 cancer cells were
significantly reduced 12 hrs following the MSeA (5 μM) treatment,
determined by quantitative RT-PCR (p< 0.05). MSeA treatment of
the cells for 24 hrs did not further inhibit Ang-2 mRNA expression. B.
Secretion of Ang-2 protein into the medium by the MDA-MB-231
cells were significantly inhibited (p< 0.05) 24 hrs following the
MSeA treatment at concentrations 5 μM or higher, as determined by
Radioimmunoassay (RCA). Compared with the PBS control, a brief
but significant increase in Ang-2 protein secretion was observed for
the MDA-MB-231 cells at 6 hrs following the 5 μM and 10 μM MSeA
treatments, and the reason is currently unknown to us.
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dependent manner [15,18-20]. Evidence indicates that
dietary selenium altered prostate proteomic profiles,
induced a set of tumor suppressor proteins [21] and
prevented chemically-induced carcinogenesis in many
rodent studies [22]. An earlier randomized, placebo-
controlled clinical trial showed significant beneficial
effects of selenium supplementation for cancer preven-
tion in patients with skin carcinoma [23]. On the other
hand, a randomized, placebo-controlled multi-centered
clinical trial (Selenium and Vitamin E Cancer Prevention
Trial, SELECT) of over 35,000 men showed selenium
or vitamin E, alone or in combination at the doses
and formulations used, did not prevent prostate cancer
[24]. While the SELECT conclusion is convincing for
the tested selenium compound of L-selenomethionine
(SeMet), certain caution may be necessary in extrapola-
tive interpretation of the results. Because ruling out
the efficacy of SeMet does not necessarily ruling out the
efficacy of all other bioactive Se forms [21,25]. Due
to the documented differences in metabolic and bio-
logical properties between SeMet and MSeA, investiga-
tion on functions of MSeA still holds promise for
potential cancer prevention.
Although previous studies showed certain selenium
compounds possess anti-tumor effects, the underlining
mechanism has not been fully elucidated. In particular,
there is no detailed data showing exactly how MSeA is
linked to inhibition of angiogenesis, a process critical for
continuation of most tumor growth. Current evidences
more or less linked to the inhibition of VEGF and
MMP2 by MSeA, as well as to the G1 arrest of cells.
In this study, we investigated the effects of MSeA on
the estrogen-independent bone metastatic mammary
cancer (MDA-MB-231) cells and the tumors induced by
the cells on athymic nude mice. We examined mRNA
transcription and protein expression of Ang-2 at several
concentration levels of MSeA on MDA-MB-231 cells,
tested VEGF levels in vitro and in vivo in response to
the MSeA treatments, compared the xenograft tumors
for weight, volume and microvascular density following
the MSeA treatment. Here we show direct evidence that
MSeA at selected concentrations caused significant re-
duction in Ang-2 mRNA transcription and Ang-2 pro-
tein secretion in MDA-MB-231 cells. Because Ang-2/
Tie2 is known as a key regulator for tumor growth
[26,27], our results help to explain the mechanism of
anti-tumor function by MSeA.
Results
MSeA significantly inhibited Ang-2 secretion
Compared with the PBS-controls, treatment of the
MDA-MB-231 mammary cancer cell cultures with
MSeA at selected non-toxic concentrations (5 μM)significantly decreased Ang-2 mRNA transcription at the
designated time intervals (Figure 1A). The inhibitory
MSeA on Ang-2 mRNA was significant 12 h after the
treatment (p< 0.05), and the prolonged treatment to
24 h did not further down regulate Ang-2 mRNA
expression.
Radioimmunoassay showed that the secretion of Ang-
2 protein by MDA-MB-231 cells into the medium was
significantly inhibited by MSeA in a concentration-
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Ang-2 mRNA transcription. The baseline secretion of
Ang-2 (MSeA=0 μM) showed a steady increase over
time, and the treatment of MSeA at lower concentration
(2.5 μM) did not significantly affect the trend of secre-
tion. In contrast, higher concentrations of MSeA
(≥5 μM) significantly reversed the levels of Ang-2 pro-
tein to the minimum 24 h following the treatment (p
< 0.05). We also noticed a brief but significant increase
in the level of Ang-2 protein at 6 hrs following the
5 μM and 10 μM MSeA treatments (Figure 1B), and the
significance of this phenomenon is currently unknown
to us.MSeA decreased level of VEGF production
Western blot experiments showed that, comparing with
the indigenous level of β-Actin, exposing MDA-MB-231
cells to MSeA treatment caused distinct reduction in the
cellular VEGF protein in a concentration-dependent
manner (Figure 2). MSeA at a lower concentration
(2.5 μM) showed no significant effect on level of VEGF
12 h after the treatment. However, the inhibition effect
was obvious at higher MSeA concentrations (5 μM andFigure 2 Western blot showing the level of vascular endothelial grow
following the treatment of MSeA at 5 μM for 12 hrs. A higher MSeA co
further inhibit the VEGF production. Commercial antihuman VEGF antibody
given MSeA concentrations and treatment time periods.10 μM). Prolonged MSeA treatment of the cells for
24 hrs did not further inhibit the VEGF protein
production.
Immunohistochemistry analysis of the tumor VEGF
showed that the xenograft tumors of athymic nude mice
induced by MDA-MB-231 cells had a distinct reduction
of VEGF following the MSeA treatment (Figure 3). Oral
administration of MSeA to the nude mice significantly
reduced the number of cells producing VEGF, as visua-
lized by the IHC staining (Figure 3B). The averaged in-
tensity score of cellular VEGF for the MSeA-treated
tumor was 1.0 (weak staining), while as the same score
for the non-MSeA treated control tumor was greater
than 2.0 (dark brown cytoplasm staining).MSeA restricted the growth of xenograft tumors
Compared with water blank controls, oral administration
of MSeA to the nude mice at 3 mg/kg/day for 18 days
significantly reduced the growth of xenograft tumors
induced by MDA-MB-231 cells (Figure 4). Average
tumor volume deceased approximately 44% in the MSeA
treatment group (Figure 4A), and the mean tumor
weight decreased approximately 46% (Figure 4B). Theth factor (VEGF) in MDA-MB-231 cells was dramatically reduced
ncentration (10 μM) or longer treatment period (24 hrs) did not
(1: 200XD) was used to visualize the cellular VEGF protein band at the
A B
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Figure 3 Immunohistochemistry (IHC) stain for VEGF showed a lower level of VEGF expression in the xenograft tumor from the
animal received MSeA-treatment. A. Control. Target VEGF protein (brown cytoplasm) was extensively and highly expressed in a MDA-MB-231
cell-induced tumor of a representative nude mouse receiving no MSeA administration as control. B. MSeA treatment. VEGF protein expression
was at a much lower percentage and level in xenograft tumor of a representative nude mouse receiving oral administration of MSeA at
3 mg/kg/day for 18 days. Scale bar = 50 μm. C. Statistical summary of VEGF positive cells for the control tumor (Mean= 234 cells/field, n = 3)
and the MSeA treatment (Mean= 45 cells/field, n = 3) (P< 0.05).
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16 days following the MSeA treatment. Meanwhile, dif-
ferences in mean body weight of the nude mice was not
significant between the MSeA-treatment (w =17.9±0.8 g;
n = 8) and the control group (w =18.7±0.7 g; n = 8).
Immunohistochemistry (IHC) staining of the xenograft
tumor sections using CD31 antibody showed that the
microvessel density for the MSeA-treated tumor was sig-
nificantly less (Figure 5B) when compared with that of
non-MSeA controls (Figure 5A). Statistical analysis
showed that the averaged microvessel density, expressed
by the CD31-positive counting per 200X-view field for
the MSeA-treatment and the control group, was 54±4
and 87±19, respectively. There was a 38% decrease in
microvessel density in the treatment group (p< 0.05).
MSeA induced microvascular maturation of the xeno-
graft tumor. IHC double-staining using CD31 and α-
SMA antibodies showed that, while the tumors from the
control group exhibited more of CD31 staining for
microvessel density (Figure 6A), the tumors receiving
MSeA treatment showed more of α-SMA staining for
pericytes (Figure 6B). The average percentage for α-
SMA stain of the MSeA-treated and the control groups
was 80±3% and 60±3%, respectively. Quantitativeanalysis of pericyte coverage showed about 20% increase
in VMI (Vascular Maturation Index) in MSeA-treated
tumors compared with the non-treated tumors (Table
6C, p< 0.05). Increased pericytes coverage is considered
as a sign of microvascular maturation, which promotes
vascular normalization.
Suppression of endogenous VEGF or Ang-2 mRNA ex-
pression by RNA interference (RNAi) in MDA-MB-231
cells showed that, while both of the levels of VEGF and
Ang-2 dropped significantly when any one of the two
was inhibited, siRNA inhibition of VEGF caused dra-
matic drop of Ang-2 expression (Figure 7). In contrast,
siRNA inhibition of Ang-2 caused less drop of VEGF
level. Our results indicate that Ang-2 was more likely
located downstream of VEGF.
Discussion
Our data showed that oral administration of MSeA to
the athymic nude mice could significantly restrict the
growth of xenograft tumors induced by mammary can-
cer MDA-MB-231 cells. Compared with the correspond-
ing controls, the anti-tumor effects of MSeA were
demonstrated in the nude mice model by significant re-
duction of xenograft tumor volume and weight,
A.
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Figure 4 Mean tumor volume (A) and tumor weight (B) of
MDA-MB-231 mammary cancer cell induced xenografts were
significantly lower (p< 0.05) in athymic nude mice receiving
single dose oral administration of MSeA at 3 mg/kg/day.
Control animals received no oral administration of MSeA.
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plus promotion of vascular maturation and normaliza-
tion by increasing pericytes coverage. The level of VEGF
was significantly decreased in the tumors of the mice
receiving the MSeA treatment. It is well known that
VEGF plays an important role in solid tumor progres-
sion by stimulating microvessel growth, which in turn
facilitates the oxygen and nutritional supply to tumors
[27,28]. Our results are consistent with and are compar-
able to the anti-tumor effects of MSeA previously
reported by other researchers [11,16,18,25,29]. The state-
ment that proper concentrations of MSeA is potentially
beneficial to human health in possessing the anti-tumor
effects have the solid support of experimental evidences,
at least in the xenograft animal models.
Our results indicate that partial inhibition of Ang-2 se-
cretion may contribute, at least in part, to the mechan-
ism of anti-tumor effects of MSeA. The levels of both
cellular VEGF and Ang-2 secretion were significantly
decreased following the MSeA treatment (Figures 1 &
2). Our results not only confirmed the previous reports
for inhibition of VEGF by MSeA [13,14], but alsodemonstrated that MSeA could significantly reduce
Ang-2 protein secretion, at least in the mammary cancer
cells. Ang-2 can be produced by both vascular endothe-
lial cells and certain cancer cells in relatively low level
[30]. The level of Ang-2 in the serum of the nude mouse
carrying the xenograft tumors was not measured due to
potential confounding of secretion by both the xenograft
tumor cells and the microvessels of mice origin. Instead
we used MDA-MB-231 cells to estimate the effect of
MSeA on Ang-2 secretion. To our knowledge, this is the
first time that MSeA is linked to inhibition of Ang-2, a
critical components in angiogenesis pathway. Our data
showed that inhibition of Ang-2 secretion was appar-
ently via the inhibition of Ang-2 mRNA transcription
(Figure 1A).
Both of our results and previous research showed that
MSeA inhibited the VEGF, which partially explain the
mechanism of action of the MSeA [13,14]. Direct evi-
dence on whether or not MSeA works simultaneously
on both VEGF and Ang-2, or it works on sequential in a
signal pathway, is currently non-conclusive to us. Since
some research showed that Ang-2 are likely placed at
the down stream of VEGF pathway and are regulated by
VEGF [31,32], it is possible that the mechanism of anti-
tumor by MSeA is to inhibit Ang-2, probably via inhibit-
ing VEGF. For the relationships between VEGF and
Ang-2, our results of the siRNA experiments are consist-
ent with the findings by Zhang et al. [32], which support
the statement that VEGF regulates the Ang-2 in the vas-
cular endothelial cells.
Demonstration of Ang-2 inhibition by MSeA treatment
has the profound significance. Ang-2 belongs to a family
of growth factors that are critically involved in blood ves-
sel formation during developmental and pathological
angiogenesis [28,33-35]. The Ang-2/Tie-2 system acts as a
vascular specific ligand/receptor system to control endo-
thelial cell survival and vascular maturation [26,36-38].
Association between MSeA and Ang-2 inhibition, there-
fore, provide additional evidence of MSeA as a plausible
candidate for certain caner prevention and treatment.
Conclusions
Our results not only showed that MSeA significantly
restricted xenograft tumor growth at the concentrations
chosen, but also demonstrate that MSeA exerts its anti-
tumor effects, at least in part, by inhibiting the Ang-2/
Tie2 pathway, probably via inhibiting VEGF.
Methods
Animals and cells
Female Balb/c athymic nude mice of 6–7 week old were
purchased from the Laboratory Animal Center, Cancer
Institute, Chinese Academy of Medical Sciences. The
colonies were maintained under the SPF condition in
C.
Microvessel density




















Figure 5 MSeA treatment significantly reduced the microvessel density of the xenograft tumor. A. Control. IHC staining for CD31 (brown)
showed that the microvessel density was much higher in xenograft tumors from the nude mice received no oral administration of MSeA. B.
MSeA treatment. Single dose oral administration of the nude mice with MSeA at 3 mg/kg/day x 18 days resulted in significant reduction in
microvessel density, as indicated by CD31 IHC staining. Scale bar = 100 μm. C. Statistical summary of the microvessel density in the treatment and
the control groups. A reduction of 38% in microvessel density was observed in the MSeA-treated nude mice (p< 0.05), with mean density for the
control and MSeA-treatment group being 87±19 and 54±4, respectively (student-t test).
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The animal usage protocols were approved in advance
by both of Animal Care and Use Committees of the
Chinese Academy of Medical Sciences and Chinese
Agricultural University.
Cultural stock of estrogen-independent mammary can-
cer cells (MDA-MB-231 cells) was purchased from
American Type Culture Collection (ATCC, HTB-26™).
Working stock of the cell lines were maintained under
standard DMEM media with 10% fetal bovine serum
and 1% penicillin/streptomycin as antibiotics (Hyclone),
in a 37 °C incubator with 5% high purity CO2.
Chemicals and reagents
Methylseleninic acid (MSeA) used was obtained com-
mercially (Sigma, #541281, CH3SeO2H, >95%). Stock
solutions of MSeA at 0.5 mg/ml and 10 mM concentra-
tion were prepared in deionized distilled water and PBS
solution, respectively; the stock solutions were filter-
sterilized and stored in 1 ml aliquots under −70 °C for
routine usage. Antibodies for CD31 (Santa Cruz, SC-
1506), α-SMA (Abcam, ab-5694), and VEGF (Santa
Cruz, SC-152) were obtained commercially and used fol-
lowing the instructions of the providers. All other chem-
icals and reagents used were at molecular biology grade.Generation of xenograft tumor model
To investigate the effect of MSeA treatment on tumor
growth, an animal model was generated by induction of
xenograft tumors using MDA-MB-231 cells in athymic
nude mice. MDA-MB-231 cells (~3X106 per animal)
were subcutaneously inoculated into the right flank of
each mouse and the animals were then randomly divided
into two groups for comparison. One group received
single-dose oral gavage administration of MSeA (3 mg/
kg BW/animal) per day for 18 days (MSeA-treatment)
and the other group received H2O as control. The
induced tumors in both groups were measured by ver-
nier calipers for volume (length × width2 × 0.5) at the
designated time intervals. At the 19th day, all the tumors
were harvested for subsequent analysis on tumor
weights, microvessel densities, and vascular maturation.
Microvessel density of the xenograft tumors was deter-
mined by immunohistochemistry (IHC) staining of the
tumor sections using CD31 antibody specific for endo-
thelial cells of microvessels [39,40]. For both MSeA-
treatment and control group, microvessel density index
was determined by counting CD31-marked endothelial
cell clusters on three chosen fields of the highest density
blood vessels at (200X) magnifying power. Quantifica-































Figure 6 MSeA facilitates vascular normalization by induction of vascular maturation. A. Control. IHC double-staining for both of CD31and
α-SMA showed that, the xenograft tumor from the nude mice with no MSeA treatment developed dense microvessels (red) but less surrounding
pericytes (brown), indicating less maturation of the microvessels; B. MSeA treatment. The IHC double-staining showed increased presentation of
α-SMA marker for pericytes (dark brown) along with the blood vessels of the tumor from the nude mice received oral administration of MSeA at
3 mg/kg/day for 18 days. Scale bar = 50 μm. C. Statistical summary of vascular density index. The Vascular Maturation Index (VMI) for the control
group and the MSeA treatment group was 60±3% and 80 ±3%, respectively (p< 0.05).
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visualize levels of VEGF in the xenograft tumors for
treatment and control groups.
Effect of MSeA on vascular maturation of the xeno-
grafts was determined by IHC double staining of the
tumor sections with both CD31 and α-SMA antibodies
[18,41]. For the MSeA-treatment and the control group,
visual counting of double-stained α-SMA/CD31 areas vs.
the positive CD31-only tissue areas was performed. Each
tumor section was examined for ten random fields under
400X magnification for statistical analysis. The blood
vessels of the MSeA treatment groups and the control
group were analyzed independently by two investigators.
Real-time PCR and Western blot
To assess whether MSeA could affect the transcriptional
levels of key genes/mRNAs potentially associated with
tumor development in MDA-MB-231 cells, total cellular
RNA from the MSeA-treated and the PBS control cells
were isolated using Trizol reagent (Invitrogen) [42]. For
the treatment, MSeA at a concentration of 5 μM as
added into the DMEM medium when cells reached
60-70% confluence. Control cells received PBS treat-
ment. Total RNAs were isolated at 12 h and 24 hafter the treatment and 2 mg of total RNA from each
group was subjected for the 1st strand cDNA synthe-
sis by reverse transcription. Quantitative PCRs were
performed with the SYBR Premix TaqReal-Time PCR
Detection System (TaKaRa) on a real-time thermal
cycler (Bio-Rad Laboratories, Inc., USA). Each qPCR
reaction was run in triplicates and relative amount of
mRNA for each gene was normalized based on house
keeping gene β-Actin. The forward and reverse primer
sequence for Ang-2 mRNA amplification was 5’-
AGATTTTGGACCAGACCAGTGA-3’ and 5’-GGAT
GATGTGCTTGTCTTCCAT-3’ respectively [22]. Total
cellular proteins were isolated from both MSeA–
treated and PBS-treated cells for Western analysis,
and VEGF antibody was used to visualize level of cel-
lular VEGF after electrophoresis.
Radioimmuno assay
To examine whether the MSeA treatment could affect
secretion of Ang-2 by MDA-MB-231 cells, radioimmuno
assay was utilized to measure the level of Ang-2 in cell
medium using a commercial Ang-2 RIA KIT (Sinoukbio,
HY174). Instructions from the kit provider were fol-
lowed in the entire experimental procedures and the
Figure 7 RNA interference of VEGF and Ang-2. MDA-MB-231 cells
were transfected with the pooled siRNAs with lipofectamine 2000
(Invitrogen). Thirty-six hours after the transfection, total RNA from
cultured cells was extracted by use of Trizol (Invitrogen). Real-time
quantitative PCR was conducted to assess the level of the target
mRNA expression using SYBR green dye, with relative changes
calculated by the ΔΔCt method. While the suppression of either of
VEGF or Ang-2 caused significant reduction of the other when
compared with the siRNA controls, inhibition of VEGF lead to a
dramatic decrease in the level of Ang-2. The results indicate that
Ang-2 is more likely regulated by VEGF.
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as to that described previously [43]. Briefly, following
the treatment of cells with MSeA at 0 μM (no treat-
ment), 2.5 μM, 5.0 μM and 10 μM concentrations after
6 h, 12 h, and 24 h period of time, 50 μl of cell culture
supernatant from each treatment was collected to meas-
ure the level of radioactivity-labeled 125I-Ang-2 in the
medium on an R-911 full-automatic radioimmuno calcu-
lating instrument. Measurement for each treatment was
conducted in triplicates.
RNA interference of VEGF and ang-2
To assess the regulation relationships between VEGF
and Ang-2 in MDA-MB-231 cells, RNA interference was
utilized to suppress the target gene expression, and
mRNA levels after the RNA interference were measured
by the real-time quantitative PCR. Three sequence-specific
siRNAs were designed for each of the target genes to en-
sure the effective suppression (Additional file 1: Table S1).
MDA-MB-231 cells were transfected with the pooled
siRNAs with lipofectamine 2000 (Invitrogen). Thirty-six
hours after transfection, total RNA from cultured cells
was extracted by use of Trizol (Invitrogen). Real-time
quantitative PCR was conducted using SYBR green dye,
with relative changes calculated by the ΔΔCt method.
Statistical analysis
All the numerical data collected in the experiments were
statistically analyzed by ANOVA or the student t-testbetween the treatments and the controls when applic-
able. The data were considered significant at p< 0.05.
Additional file
Additional file 1: Table S1. cDNA sequences of VEGF and Ang-2 siRNAs.
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